S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Germany, EU reach agreement in combustion engine row
Judge rules online archive's book service violated copyright
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Finnish leadership condemns attack on veteran lawmaker
Venezuela: 21 officials, businessmen arrested in oil scheme
OTCMKTS:ATBPD

Antibe Therapeutics - ATBPD Stock Forecast, Price & News

$0.44
-0.02 (-4.35%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.44
$0.44
50-Day Range
$0.36
$0.53
52-Week Range
$2.64
$3.50
Volume
12,000 shs
Average Volume
29,710 shs
Market Capitalization
$170.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ATBPD stock logo

About Antibe Therapeutics (OTCMKTS:ATBPD) Stock

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Receive ATBPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATBPD Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive ATBPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ATBPD
CIK
N/A
Fax
N/A
Employees
47
Year Founded
N/A

Profitability

Net Income
$-14,540,000.00
Net Margins
-273.96%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.51 million
Book Value
$0.10 per share

Miscellaneous

Free Float
N/A
Market Cap
$170.05 million
Optionable
Not Optionable
Beta
0.57

Key Executives

  • Mr. Daniel Marcel Legault (Age 62)
    Pres, CEO, Sec. & Director
  • Dr. John Lawrence Wallace M.B.A. (Age 63)
    M.Sc., MSc, Ph.D., MBA, Founder, Chief Scientific Officer & Director
  • Mr. Alain Wilson M.B.A.
    MBA, Chief Financial Officer
  • Dr. David James Vaughan (Age 70)
    Chief Devel. Officer
  • Mr. Scott Curtis C.F.A.
    M.Eng, CFA, Exec. VP
  • Ms. Christina Cameron B.B.A.
    VP of Investor Relations
  • Mr. Philip Stern
    VP of Communications
  • Dr. Rami Batal M.B.A.
    Ph.D., Chief Commercial Officer
  • Ms. Ella Korets Smith M.B.A.
    M.Sc., Head of Regional Bus. Devel.
  • Dr. Joseph Stauffer (Age 54)
    Chief Medical Officer













ATBPD Stock - Frequently Asked Questions

How have ATBPD shares performed in 2023?

Antibe Therapeutics' stock was trading at $0.3230 at the beginning of 2023. Since then, ATBPD shares have increased by 36.0% and is now trading at $0.4394.
View the best growth stocks for 2023 here
.

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the OTCMKTS under the ticker symbol "ATBPD."

How do I buy shares of Antibe Therapeutics?

Shares of ATBPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Antibe Therapeutics' stock price today?

One share of ATBPD stock can currently be purchased for approximately $0.44.

How much money does Antibe Therapeutics make?

Antibe Therapeutics (OTCMKTS:ATBPD) has a market capitalization of $170.05 million and generates $7.51 million in revenue each year. The company earns $-14,540,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How can I contact Antibe Therapeutics?

Antibe Therapeutics' mailing address is 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2. The official website for the company is www.antibethera.com. The company can be reached via phone at 416 922 3460 or via email at christina@antibethera.com.

This page (OTCMKTS:ATBPD) was last updated on 3/26/2023 by MarketBeat.com Staff